Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org comes to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.

Tags: immunotherapy

9/12/2018

Reuters story on kidney cancer drug makes us ask: How is this journalism?

4/17/2018

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

4/17/2018

Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark

10/24/2017

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

9/21/2017

AP’s story on cancer immunotherapy quickly mentions low success rate

7/18/2017

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

7/13/2017

It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’

6/1/2017

Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results

5/22/2017

Keytruda for bladder cancer: No independent scrutiny of Merck-reported results

4/4/2017

‘Promising’ new lymphoma treatment gets superficial, one-sided coverage by CBS